CBS 2019
CBSMD教育中心
中 文

经皮左心耳封堵

Abstract

Recommended Article

Left atrial appendage occlusion in atrial fibrillation patients with previous intracranial bleeding: A national multicenter study EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update Atrial Fibrillation: JACC Council Perspectives An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction Initial Worldwide Experience With the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Atrial Fibrillation Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO System) to Prevent Stroke in High-Risk Patients With Non-Rheumatic Atrial Fibrillation: Results From the International Multi-Center Feasibility Trials Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation: A Randomised Non-Inferiority Trial

Original ResearchVolume 73, Issue 19, May 2019

JOURNAL:J Am Coll Cardiol. Article Link

Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention

P Guedeney, BE Claessen, DN Kalkman et al. Keywords: inflammation; LDL-C; PCI; MACCE

ABSTRACT


BACKGROUND - Data on the impact of residual inflammatory risk (RIR) in patients undergoing percutaneous coronary intervention (PCI) with baseline low-density lipoprotein cholesterol (LDL-C) 70 mg/dl are scarce.

OBJECTIVES - The purpose of this study was to characterize the prevalence and impact of persistent high RIR after PCI in patients with baseline LDL-C 70 mg/dl.

METHODS - All patients undergoing PCI between January 2009 and December 2016 in a single tertiary center, with baseline LDL-C 70 mg/dl and serial high-sensitivity C-reactive protein (hsCRP) assessments (at least 2 measurements 4 weeks apart) were retrospectively analyzed. High RIR was defined as hsCRP >2 mg/l. Patients were categorized as persistent low RIR (first low then low hsCRP), attenuated RIR (first high then low hsCRP), increased RIR (first low then high hsCRP), or persistent high RIR (first high then high hsCRP). Primary endpoint of interest was major adverse cardiac and cerebrovascular accident (MACCE) (death, myocardial infarction, or stroke), within 1 year of the second hsCRP measurement.

RESULTS - A total of 3,013 patients were included, with persistent low, attenuated, increased, and persistent high RIR in 1,225 (41.7%), 414 (13.7%), 346 (11.5%), and 1,028 (34.1%) patients, respectively. Overall, there was a stepwise increase in the incidence rates of MACCE, transitioning from the persistent low to the attenuated, increased, and persistent high RIR (respectively, 64.4 vs. 96.6 vs. 138.0 vs. 152.4 per 1,000 patient-years; p < 0.001). After adjustment, the presence of persistent high RIR remained strongly associated with MACCE (adjusted hazard ratio: 2.10; 95% confidence interval: 1.45 to 3.02; p < 0.001).

CONCLUSIONS - Among patients undergoing PCI with baseline LDL-C 70 mg/dl, persistent high RIR is frequent and is associated with increased risk of MACCE. Targeting residual inflammation in patients with optimal LDL-C control may further improve outcomes after PCI.